Hepatitis C therapy—the future looks bright

Review

DOI: 10.1007/s10096-009-0798-1

Cite this article as:
Qureshi, S.A., Qureshi, H. & Hameed, A. Eur J Clin Microbiol Infect Dis (2009) 28: 1409. doi:10.1007/s10096-009-0798-1

Abstract

Hepatitis C virus (HCV) infections affect about 170 million individuals worldwide and can be life-threatening if left untreated. Over the past three decades, ribavirin and interferon-α have remained the only available medicines for treating hepatitis C sufferers. Given that this combination therapy is partially effective at best and is associated with severe side-effects, there is an unmet need for new molecular entities which inhibit HCV replication. By employing a combination of structure-based drug design together with high-throughput screening approaches, several pharmaceutical companies have been successful in identifying potentially useful compounds for treating HCV infections. This article provides an overview of some of the small-molecule inhibitors that have shown promise so far in clinical trials and which could reach the clinic within the next three years.

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Sohail A. Qureshi
    • 1
  • Humaira Qureshi
    • 1
  • Anam Hameed
    • 2
  1. 1.Department of Biological & Biomedical SciencesThe Aga Khan University HospitalKarachiPakistan
  2. 2.Medical CollegeThe Aga Khan University HospitalKarachiPakistan

Personalised recommendations